Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386191503> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4386191503 endingPage "s757" @default.
- W4386191503 startingPage "s749" @default.
- W4386191503 abstract "Abstract: Background and Aim: Based on inhibitors of DPP-IV, there is a fantastic method for creating anti-diabetic medications. These inhibitors regulate diabetic patients' blood sugar levels to prevent difficulties with their health. In the current work, we created a brand-new series of compounds Cyclopyrrolidine clubbed with oxadiazole bases. Materials and Methods: Cyclopyrrolidine clubbed with oxadiazole bases (B-1 to B-16) were synthesized and characterized through IR, NMR, mass spectrometry, and elemental analysis. Docking studies were performed to assess interactions and binding modes of synthesized hits at the binding site of receptor DPP-4 (PDB 3W2T). Using vildagliptin as a standard drug, six of the synthesized compounds were tested for their antidiabetic activity in diabetic rats induced with HFD-STZ-Nicotinamide. Results: The results showed that compound B-XIV (220*4.56B) resulted in the greatest reduction in blood glucose level from all synthesized compounds compared to that of vildagliptin (215*7.52B) in HFD-STZ-Nicotinamide. Other compounds showed moderate to good antihyperglycemic activity. Conclusion: From he presents work it can be concluded that synthesized compounds possess good DPP-IV inhibitory activity. Compounds containing electron-withdrawing groups (chlorine, nitro, methoxy) were displayed a good anti-diabetic effect than electron-donating groups (methyl, hydroxyl). Oxadiazole derivatives could be used for further development to obtain more promising drug candidates. Keywords: Furadiazole, Hyperglycaemic, HFD-STZ-Nicotinamide." @default.
- W4386191503 created "2023-08-27" @default.
- W4386191503 creator A5035290008 @default.
- W4386191503 creator A5092700237 @default.
- W4386191503 date "2023-08-23" @default.
- W4386191503 modified "2023-09-30" @default.
- W4386191503 title "Synthesis of Cyclopyrrolidine Clubbed with Oxadiazole Bases and Evaluation of their Anti-Diabetic Activity through in vivo Model" @default.
- W4386191503 doi "https://doi.org/10.5530/ijper.57.3s.85" @default.
- W4386191503 hasPublicationYear "2023" @default.
- W4386191503 type Work @default.
- W4386191503 citedByCount "0" @default.
- W4386191503 crossrefType "journal-article" @default.
- W4386191503 hasAuthorship W4386191503A5035290008 @default.
- W4386191503 hasAuthorship W4386191503A5092700237 @default.
- W4386191503 hasBestOaLocation W43861915031 @default.
- W4386191503 hasConcept C134018914 @default.
- W4386191503 hasConcept C150903083 @default.
- W4386191503 hasConcept C178790620 @default.
- W4386191503 hasConcept C181199279 @default.
- W4386191503 hasConcept C185592680 @default.
- W4386191503 hasConcept C207001950 @default.
- W4386191503 hasConcept C21951064 @default.
- W4386191503 hasConcept C2776453732 @default.
- W4386191503 hasConcept C2779448499 @default.
- W4386191503 hasConcept C2779728014 @default.
- W4386191503 hasConcept C2780035454 @default.
- W4386191503 hasConcept C2780323712 @default.
- W4386191503 hasConcept C2780485761 @default.
- W4386191503 hasConcept C55493867 @default.
- W4386191503 hasConcept C555293320 @default.
- W4386191503 hasConcept C71240020 @default.
- W4386191503 hasConcept C71924100 @default.
- W4386191503 hasConcept C86803240 @default.
- W4386191503 hasConcept C98274493 @default.
- W4386191503 hasConceptScore W4386191503C134018914 @default.
- W4386191503 hasConceptScore W4386191503C150903083 @default.
- W4386191503 hasConceptScore W4386191503C178790620 @default.
- W4386191503 hasConceptScore W4386191503C181199279 @default.
- W4386191503 hasConceptScore W4386191503C185592680 @default.
- W4386191503 hasConceptScore W4386191503C207001950 @default.
- W4386191503 hasConceptScore W4386191503C21951064 @default.
- W4386191503 hasConceptScore W4386191503C2776453732 @default.
- W4386191503 hasConceptScore W4386191503C2779448499 @default.
- W4386191503 hasConceptScore W4386191503C2779728014 @default.
- W4386191503 hasConceptScore W4386191503C2780035454 @default.
- W4386191503 hasConceptScore W4386191503C2780323712 @default.
- W4386191503 hasConceptScore W4386191503C2780485761 @default.
- W4386191503 hasConceptScore W4386191503C55493867 @default.
- W4386191503 hasConceptScore W4386191503C555293320 @default.
- W4386191503 hasConceptScore W4386191503C71240020 @default.
- W4386191503 hasConceptScore W4386191503C71924100 @default.
- W4386191503 hasConceptScore W4386191503C86803240 @default.
- W4386191503 hasConceptScore W4386191503C98274493 @default.
- W4386191503 hasIssue "3s" @default.
- W4386191503 hasLocation W43861915031 @default.
- W4386191503 hasOpenAccess W4386191503 @default.
- W4386191503 hasPrimaryLocation W43861915031 @default.
- W4386191503 hasRelatedWork W1982451187 @default.
- W4386191503 hasRelatedWork W2020638064 @default.
- W4386191503 hasRelatedWork W2022995595 @default.
- W4386191503 hasRelatedWork W2059241568 @default.
- W4386191503 hasRelatedWork W2419366834 @default.
- W4386191503 hasRelatedWork W2438771022 @default.
- W4386191503 hasRelatedWork W2770007752 @default.
- W4386191503 hasRelatedWork W2782734952 @default.
- W4386191503 hasRelatedWork W3176227937 @default.
- W4386191503 hasRelatedWork W646186600 @default.
- W4386191503 hasVolume "57" @default.
- W4386191503 isParatext "false" @default.
- W4386191503 isRetracted "false" @default.
- W4386191503 workType "article" @default.